Treatment patterns and survival in HER2-positive early breast cancer: a whole-of-population Australian cohort study (2007–2016)

BACKGROUND: Randomised clinical trials (RCTs) demonstrate that trastuzumab improves survival in patients with human epidermal growth factor 2-positive early breast cancer (HER2 + EBC), but real-world patients and clinical practice often differ from RCTs. We examine real-world treatment patterns and...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Monica, Schaffer, Andrea, Kiely, Belinda E., Daniels, Benjamin, Simes, Robert J., Lee, Chee K., Pearson, Sallie-Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889396/
https://www.ncbi.nlm.nih.gov/pubmed/31673103
http://dx.doi.org/10.1038/s41416-019-0612-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889396/
https://www.ncbi.nlm.nih.gov/pubmed/31673103
http://dx.doi.org/10.1038/s41416-019-0612-5

Ejemplares similares